<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03780127</url>
  </required_header>
  <id_info>
    <org_study_id>ZX008-1800</org_study_id>
    <nct_id>NCT03780127</nct_id>
  </id_info>
  <brief_title>ZX008 Expanded Access Protocol</brief_title>
  <official_title>ZX008 Expanded Access Protocol - Dravet Syndrome Treatment Plan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zogenix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zogenix, Inc.</source>
  <brief_summary>
    <textblock>
      The treatment plan for this Expanded Access Protocol is for patients with Dravet syndrome who
      do not qualify for participation in one of the ongoing ZX008 clinical trials.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment plan consists of an up to 12-month Treatment Period. Access is via application
      by your health care provider and available at one of the Expanded Access treatment centers.
      The dose of ZX008 for the duration of the Treatment Period will range from 0.2 mg/kg/day to a
      maximum of 0.8 mg/kg/day, not to exceed a total daily dose of 30 mg/day; for patients
      concurrently being prescribed stiripentol, the maximum will be 0.5mg/kg/day, not to exceed a
      total daily dose of 20 mg/day.

      The fenfluramine US Expanded Access Program (US EAP) is available to full-time US Residents
      only.

      Participation in the US EAP is limited to patients currently residing in the US. Residency in
      the US must be for the duration of participation in the US EAP. Drug may not be shipped
      outside the US.
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Dravet Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenfluramine Hydrochloride</intervention_name>
    <description>ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free and is intended to be compatible with KD.</description>
    <other_name>ZX008</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is male or female, age 2 years and older, inclusive as of Study Day 1.

          -  Patient is diagnosed with Dravet syndrome.

          -  Patient is experiencing convulsive seizures which are not controlled by current AEDs.

          -  Patient is receiving at least one AED and will remain on at least one AED for the
             duration of treatment.

          -  Patient has been approved for inclusion by Zogenix.

        Exclusion Criteria:

          -  Patient requires or starts using an unacceptable or contraindicated concomitant
             medication.

          -  Patient has valvulopathy.

          -  Patient is at risk for pulmonary hypertension.

          -  Patient exclusion will be at the sole discretion of the Sponsor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>ZX008 Clinical Trials Information Desk</last_name>
    <phone>510-338-9968</phone>
    <email>ClinStudyInfo@zogenix.com</email>
  </overall_contact>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>December 14, 2018</study_first_submitted>
  <study_first_submitted_qc>December 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2018</study_first_posted>
  <last_update_submitted>August 21, 2019</last_update_submitted>
  <last_update_submitted_qc>August 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsies, Myoclonic</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenfluramine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

